In a bid to revolutionize patient care, Medline announces its partnership with Consure Medical for exclusive distribution of the QiVi® MEC, aiming to combat urinary tract infections and dermatitis in acute care hospitals across the United States.
In a significant development in the healthcare sector, Medline, a prominent medical supply manufacturer and distributor, has announced a strategic partnership with Consure Medical to exclusively distribute a revolutionary new product—the QiVi® MEC—to acute care hospitals across the United States. This male external urine management device represents a significant advancement in patient care, designed to combat two common and troublesome conditions: catheter-associated urinary tract infections (CAUTI) and incontinence-associated dermatitis (IAD).
Catheter-associated urinary tract infections and the discomfort caused by incontinence-associated dermatitis are pervasive complications in healthcare settings, affecting patient well-being, prolonging hospital stays, and increasing healthcare costs. These issues are particularly prominent among patients requiring long-term catheterization or those suffering from incontinence. Historically, options for managing male urinary incontinence have been limited, often uncomfortable, and sometimes prone to causing additional health complications.
Enter the QiVi MEC, a standout innovation in the field of urology and patient care. Unlike traditional methods that rely on absorbent materials or indwelling catheters, the QiVi MEC device employs a non-invasive, suction-based system to manage urine output. This approach not only prevents the common complications associated with internal catheters and external sheaths but also keeps the skin dry, significantly reducing the risk of dermatitis. Furthermore, the device’s precise urine collection and measurement capability is an invaluable tool for healthcare professionals, enabling better fluid management and clinical assessments.
Medline’s decision to incorporate the QiVi MEC into its portfolio underscores the company’s commitment to providing cutting-edge solutions that address critical healthcare challenges while prioritizing patient comfort and clinical outcomes. According to Mike Gerskovich, General Manager of Urology at Medline, the QiVi MEC bridges the gap between infection prevention and wound care, offering a comprehensive approach to lowering hospital-acquired infections. The device’s universal fit and skin-friendly, silicon-based adhesive further enhance its appeal, making it a viable option for a broad range of patients.
Nish Chasmawala, co-founder & CEO of Consure Medical, expressed excitement over the collaboration with Medline, highlighting the potential for the QiVi MEC to become a standard of care in acute settings across the country. Consure’s dedication to developing innovative products that improve clinical outcomes, enhance patient dignity, and reduce healthcare expenditures aligns with Medline’s mission to deliver high-quality care solutions.
As Medline and Consure Medical embark on this exclusive distribution agreement, the healthcare industry anticipates a noteworthy shift in how male urinary incontinence is managed in acute care settings. This collaboration not only represents a leap forward in patient care technologies but also exemplifies the impactful results that can be achieved when companies with shared goals join forces. The integration of the QiVi MEC into Medline’s robust urology portfolio is expected to set new standards in the sector, ultimately leading to improved patient experiences and outcomes.
For healthcare professionals and patients alike, the launch of the QiVi MEC marks a new chapter in the ongoing effort to address and mitigate the challenges associated with urinary management in clinical settings. As this innovative device becomes more widely available, it promises to make a significant impact on the quality of care provided to countless individuals, reaffirming the critical role of technological advancement in advancing healthcare.